SRX sierra rutile holdings limited

News: SRX Sirtex Medical provides FY ending June 2017 guidance

  1. 193,698 Posts.
    lightbulb Created with Sketch. 2825

    Dec 9 (Reuters) - Sirtex Medical Ltd (SRX) :

    • On a full year basis, worldwide dose sales growth is anticipated to be in order of 5-11% compared to growth of 16.4% achieved in fy16
    • Constant currency EBITDA for full year is anticipated to be in range $65-74 million
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.